Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBCombination therapies in CLL are generating excitement with ongoing trials that could expand standard practice for the future. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Breast Cancer | Oncology News & Insights | Targeted Oncology
WEBSep 19, 2024 — Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting. Jordyn Sava. July 12th 2024. In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Managing Chemotherapy Toxicities for Improved Patient Outcomes
WEBMar 29, 2021 — In a large majority of patients, even when treating with chemotherapy that is highly emetogenic, nausea and vomiting can be prevented. Options include 5-HT3 receptor antagonists (such as ondansetron), NK-1 receptor antagonists (such as aprepitant), glucocorticoids (such as dexamethasone), and olanzapine, a …
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 — Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
FDA Grants Breakthrough Therapy Designation to SNDX-5613 for …
WEBDec 6, 2022 — The FDA has granted a breakthrough therapy designation (BTD) to SNDX-5613 (revumenib) for the treatment of adult and pediatric patients with relapsed or refractory (R/R) acute leukemia harboring a KMT2A rearrangement (KMT2Ar). 1. Phase 1 data from the AUGMENT-101 trial (NCT04065399) support the BTD. In …
The Potential of STING Agonists Is Explored in Cancer
WEBMar 30, 2022 — Stimulator of interferon genes (STING) is an endoplasmic protein that induces the production of proinflammatory cytokines and has become a target of interest to obtain or boost antitumor immune responses. 1 First-generation STING agonists are structurally unstable, which has driven development of compounds with greater stability and …
IGHV and TP53 Remain Important Prognostic CLL Biomarkers
WEBSep 9, 2021 — IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia (CLL), despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients, according to a debate that took place during the 2021 SOHO Annual Meeting. 1,2. Although several markers of CLL activity and growth, notably IGHV and ...
Docetaxel Continues to Show Profound Benefits in Prostate Cancer
WEBJan 14, 2017 — In the larger STAMPEDE trial (2962 patients), adding docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer. The median overall survival (OS) was 81 months with docetaxel plus standard of care (hormonal therapy with or …
Long-Term Darolutamide Displays Favorable Safety Profile in …
WEBMay 14, 2022 — The median baseline prostate-specific antigen level was 9.25 μg/L (range, 4.6-22.6). Investigators found with these long-term treatment data that the safety and tolerability of darolutamide in patients with mCRPC was favorable and consistent with previous study findings, such as the phase 3 ARAMIS (NCT02200614) and ARASENS (NCT02799602) trials.
Diagnosis, Staging, and Testing for Nonsquamous NSCLC
WEBNov 21, 2017 — 1 NSCLC originates from lung epithelial cells of the central bronchi to terminal alveoli, 2 nonsquamous NSCLC will generally originate in peripheral lung tissue, and squamous cell carcinoma (SCC) primarily originates near a central bronchus.. Lung cancer, including both NSCLC and SCLC, contributes to the most cancer-related deaths in the United States, with 155,870 deaths estimated for 2017. 2 ...